An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B.

Trial Profile

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary) ; Vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jul 2014 According to a GlaxoSmithKline media release, Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Anoro-Ellipta (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with COPD.
    • 11 Sep 2013 Pooled analysis results for patient use and subject device preference questionnaire presented at the 23rd Annual Congress of the European Respiratory Society.
    • 11 Sep 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met according to results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top